ExeVir Bio, a Ghent, Belgium-based biotech company developing nanobody therapies for broad protection against infectious diseases, raised €25M in Venture Debt financing.
European Investment Bank provided the loan.
The company intends to use the funds to advance its lead asset, XVR012, into clinical trials for COVID-19.
Led by CEO Torsten Mummenbrauer and COO Fiona du Monceau, ExeVir Bio is a clinical stage biotechnology company developing nanobody based therapeutics focusing on infectious diseases. The company is harnessing its llama-derived antibody (VHH) technology platform to generate multi-specific antibodies for prophylaxis and treatment of infectious diseases. ExeVir’s initial focus is on prevention of COVID-19 for the immunocompromised patient population where there remains a high unmet need due to the limitations of current vaccines and therapeutic approaches. Its lead asset, XVR012, is a COVID-19 neutralizing antibody that targets the S1 and S2 region of the coronavirus.
ExeVir is a spin out of VIB, the Belgium-based life sciences research institute. It is backed by investors including Fund+, which led the series A of € 42M, together with an international consortium including UCB Ventures, FPIM, V-Bio Ventures, VIB, SRIW, Noshaq, Vives IUF and SambrInvest. ExeVir has received, support from VLAIO, the SPW-Recherche and the European Union, leading to a total of €16.5M in non-dilutive funding.
FinSMEs
09/01/2023